Phosphoantigen prodrug compound

JP7695789B2Active Publication Date: 2025-06-19UNIV COLLEGE CARDIFF CONSULTANTS LTD +1
-1 Cites 1 Cited by

Patent Information

Application Number
JP2020573466
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-07-04
Filing Date
2019-07-03
Publication Date
2025-06-19
Estimated Expiration
2039-07-03

Smart Images

  • Figure 0007695789000012
    Figure 0007695789000012
  • Figure 0007695789000013
    Figure 0007695789000013
  • Figure 0007695789000014
    Figure 0007695789000014
Patent Text Reader

Abstract

The present invention relates to compounds of general formula (I), wherein R1, R2, R3, R4, and R5 are defined in the specification. These compounds and compositions containing the compounds exhibit high serum stability and potent activation of γδ T cell immune responses, making them suitable for use in immunotherapy. The present invention also relates to methods of immunotherapy using compounds of general formula (I). [Selection diagram] Figure 13
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Anti-cancer phosphonate analogs

    JP2010535701A

  • Process for the production of monoalkyl phosphonic acid diesters, diamides, and dihalides

    US3149144A

  • Medicament for oral application, containing aminopropyl phosphonic acid esters as an active ingredient

    WO2002008235A1

  • Improved methods of using phosphoantigens for the treatment of diseases

    WO2010049438A2

  • Prodrugs of prostate specific membrane antigen (PSMA) inhibitor

    WO2016022827A1

Cited By

  • Phosphoantigen prodrug compounds

    JP2024116239A